RE:RE:RE:RE:RE:RE:RE:RE:GENEREX INKS $50 MILLION LICENSING DEAL WITH CHINA PARTNERS A double blind test in covid-19 situation likely don’t prove anything close to effectivity. Volunteers don’t know if they got the placebo or the real thing, therefore volunteers still are wearing preventive facemask mask and face shields in their everyday lives. Its different from the way the usual vaccines are tested, wherein subjects have no restrictions, but covid-19 has. People are wearing mask and PPE, therefore there is a good chance that those mask and PPE and the real cause of not being infected and not being immune because of the vaccine. The only way to know is no mask and check who gets infected and not.
bigbanktheory wrote: bligicka wrote: In my opinion yes they need a advantage over those competitors and others that may even raise the bar further......has their been any failures as of yet ???
bigbanktheory wrote: Padina wrote: No its not a waste of time. The liitle funds from PP is needed to take them to a ceratin milestone which will make them an ideal candidate for a partnership or qualify them for a grant.
Partners want something with little or no risk , A positive Army result wil greatly de-risk VXL and it will also give leverage to vxl on the negotiating table.
The big companies coming out with 90-95% positive results???? And don't quote me on that. Pretty high standard. But not perfect. So does VXL have to be perfect????? Glta, all just a guess and do your dd
Is it possible that even if a company fails, their science could be a small part of the solution???